Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Cost of RevenueGross ProfitLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

RedHill Biopharma (RDHL) Cost of Revenue (2017 - 2023)

RedHill Biopharma has reported Cost of Revenue over the past 8 years, most recently at $806000.0 for Q2 2023.

  • Quarterly Cost of Revenue fell 91.04% to $806000.0 in Q2 2023 from the year-ago period, while the trailing twelve-month figure was $20.5 million through Jun 2023, down 53.33% year-over-year, with the annual reading at -$5.2 million for FY2025, 100.0% down from the prior year.
  • Cost of Revenue was $806000.0 for Q2 2023 at RedHill Biopharma, down from $1.6 million in the prior quarter.
  • Over five years, Cost of Revenue peaked at $19.3 million in Q4 2021 and troughed at $417000.0 in Q1 2019.
  • The 5-year median for Cost of Revenue is $8.8 million (2022), against an average of $6.9 million.
  • Year-over-year, Cost of Revenue soared 3238.35% in 2020 and then plummeted 91.04% in 2023.
  • A 5-year view of Cost of Revenue shows it stood at $788000.0 in 2019, then surged by 1251.78% to $10.7 million in 2020, then surged by 81.51% to $19.3 million in 2021, then crashed by 55.53% to $8.6 million in 2022, then crashed by 90.63% to $806000.0 in 2023.
  • Per Business Quant, the three most recent readings for RDHL's Cost of Revenue are $806000.0 (Q2 2023), $1.6 million (Q1 2023), and $8.6 million (Q4 2022).